Development and validation of a LC-FL method for the simultaneous determination of doxorubicin and celecoxib in nanoparticulate fixed dose combination (NanoFDC)
PHARMAZIE, vol.72, no.10, pp.568-570, 2017 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 72 Issue: 10
- Publication Date: 2017
- Doi Number: 10.1691/ph.2017.7077
- Journal Name: PHARMAZIE
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.568-570
- Hacettepe University Affiliated: Yes
Abstract
An isocratic reversed phase HPLC method for the simultaneous determination of doxorubicine (DOX) and celecoxib (CXB) out of a nanoparticulate fixed dose combination (NanoFDC) was developed and validated. Linearity of the results was demonstrated from 1-11 mu g/mL for both components. Lower limits of detection were determined as 7 ng/mL for DOX and 13 ng/mL for CXB. Total run time was approximately 15 min.